

FORM 51 – 102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

BioMark Diagnostics Inc. (“the Issuer”)
165 – 10551 Shellbridge Way
Richmond, BC V6X 2W8

Item 2: Date of Material Change

December 5th, 2017

Item 3: News Release

A news release was issued and disseminate on December 5th, 2017 and filed on SEDAR (www.sedar.com).
A copy of the news release is attached as Schedule “A” hereto.

Item 4: Summary of Material Change

The Company is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company.

Item 5: Full Description of Material Change

Please see attached Schedule “A”

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7: Omitted Information

None

Item 8: Executive Officer

Rashid Ahmed Bux, President & CEO
Telephone: 604.282.6567
Email: info@biomarkdiagnostics.com

Item 9: Date of Report

December 5th, 2017



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

Dr. IAN SMITH JOINS BIOMARK'S BOARD OF DIRECTORS

Vancouver, British Columbia – (December 5th, 2017)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company.

Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Smith to our board. His achievements in medical research space will be a major asset to BioMark. Dr. Smith’s diagnostic expertise, leadership and research experience brings depth and practicality as we begin to commercialize and position our technology for different oncology applications and potential linkages with strategic distribution partners.”

About Dr. Ian C.P. Smith, O.C., OFS, Ph.D., D.Sc., FRS(C)

Dr. Ian Smith is the Chair of CIMTEC's Board of Directors. Dr. Smith began his National Research Council (NRC) career in Ottawa as a Research Officer specializing in magnetic resonance. In 1987, he became Director General of the NRC Institute for Biological Sciences, Ottawa. In 1992, he founded the Institute for Biodiagnostics in Winnipeg as its first Director General. The Institute focuses on the development and commercialization of medical devices for the non-invasive diagnosis of disease.

Dr. Smith is dedicated to early detection and treatment of disease and using this knowledge to advance the state of medicine and the economy. He is a passionate mover for the commercialization of the products of research, and has started nine companies with a present value of \$300 million. In 2013, he retired from NRC to help build a spin-off company, Innovative Biodiagnostics, specializing in tests for colon cancer and breast cancer.

He was appointed Officer of the Order of Canada in 2008 for his leadership in the advancement, development and commercialization of Canada’s diagnostic technologies, notably magnetic resonance imaging, in the field of health care. In addition, Dr. Smith received the 2008 Outstanding Achievement Award of the Public Service of Canada, presented to individuals who have displayed long-term excellence throughout their careers in Canada's public service. He was awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for his contributions.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <http://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release